Repare Therapeutics

Repare Therapeutics is a clinical-stage precision oncology company focused on developing novel therapies based on synthetic lethality. Their proprietary SNIPRx platform utilizes CRISPR-based screening to identify and develop highly targeted cancer therapies that address genomic instability, including DNA damage repair. This approach allows them to identify synthetic lethal gene pairs and develop drugs that selectively target cancer cells with specific genetic alterations, while sparing healthy cells.

Repare has a diverse pipeline of product candidates, including lunresertib, a PKMYT1 inhibitor, and camonsertib, a potential leading ATR inhibitor. They are also developing inhibitors for PLK4 and Polθ. The company is committed to advancing these therapies through clinical trials and ultimately delivering innovative treatments for patients with cancer. Repare's focus on synthetic lethality has positioned them as a leader in the precision oncology field, with the potential to significantly impact cancer treatment.

Repare Therapeutics is a clinical-stage precision oncology company committed to developing innovative synthetic lethality therapies for cancer patients. They utilize their proprietary SNIPRx® platform, a genome-wide CRISPR-enabled technology, to identify and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Their goal is to become the leading biopharmaceutical company developing precision oncology, small molecule therapies based on synthetic lethality, offering patients with high unmet medical needs access to life-changing treatments.

Repare Therapeutics cultivates a fast-paced, collaborative, and innovative work environment where employees are encouraged to take on challenges and contribute to a shared mission of impacting the lives of cancer patients. The company values results, resilience, collaboration, transformation, and innovation, fostering a culture of respect, trust, and a genuine desire to make a difference in the fight against cancer.

Repare Therapeutics prioritizes a culture of respect, trust, and inclusivity, believing that diversity of thought and background fosters innovation and leads to better outcomes for cancer patients. They actively promote an environment where all employees feel valued and empowered, regardless of their background, allowing them to contribute their unique perspectives and talents to the company's mission. This commitment is reflected in their stated core values, which emphasize respect, empathy, and openness.